Treatment decisions in a man with Hodgkin lymphoma and Guillian-Barré syndrome: a case report

Hughes, Caren L.; Yorio, Jeffrey T.; Kovitz, Craig; Oki, Yasuhiro
December 2014
Journal of Medical Case Reports;2014, Vol. 8 Issue 1, p567
Academic Journal
Case Study
Introduction Guillain-Barre syndrome, or acute inflammatory demyelinating polyneuropathy, has been described in the presence of malignancies such as lymphoma. Guillain-Barre syndrome/acute inflammatory demyelinating polyneuropathy causes paresthesias and weakness, which can make the treatment of lymphoma with chemotherapy challenging. Given the rarity of this copresentation it is not known if the effects of Guillain-Barre syndrome should be considered when selecting a treatment regimen for Hodgkin lymphoma. To the best of our knowledge, the impact of these treatment modifications has not been previously reported. Case presentation We report the case of a 37-year-old Caucasian man with a diagnosis of stage IIB classical Hodgkin lymphoma with concomitant Guillain-Barre syndrome. Our patient originally presented with an enlarged cervical lymph node and quickly developed distal paresthesia and progressive weakness of all four extremities. He was diagnosed with Hodgkin's lymphoma and initiated on treatment with doxorubicin, bleomycin, vinblastine, and dacarbazine. Doses of bleomycin and vinblastine were held or dose-reduced throughout his initial treatment course due to underlying neuropathy and dyspnea. He continued to have persistent disease after five cycles of doxorubicin, bleomycin, vinblastine, and dacarbazine and went on to receive salvage treatments including more chemotherapy, radiation, autologous stem cell transplant and is currently preparing for an allogeneic stem cell transplant. Conclusions Paraneoplastic syndromes such as Guillain-Barre syndrome/acute inflammatory demyelinating polyneuropathy can make the treatment of patients with Hodgkin lymphoma more challenging and can interfere with delivering full-dose chemotherapy. Further case series are needed to evaluate the effect that paraneoplastic syndromes, or adjustments made in therapy due to these syndromes, negatively affect the prognosis of patients with Hodgkin lymphoma.


Related Articles

  • Research & Markets: Brentuximab Vedotin - First Treatment Option for Relapsed Hodgkin Lymphoma and Anaplastic Large Cell Lymphoma (Subset of Non-Hodgkin Lymphoma).  // Biomedical Market Newsletter;8/23/2011, Vol. 21, p77 

    The article discusses the need for drugs with enhanced toxicity and efficacy in treating Hodgkin and non-Hodgkin lymphoma. It says that the relapse rate for Hodgkin lymphoma and anaplastic large cell lymphoma (ALCL) patients are 30% and 50%. It mentions the report "Brentuximab Vedotin: First...

  • ABVD in older patients with early-stage Hodgkin lymphoma treated within the German Hodgkin Study Group HD10 and HD11 trials. Fox, Christopher // Current Medical Literature: Leukemia & Lymphoma;2013, Vol. 21 Issue 3, p82 

    The article discusses research on the safety and efficacy of doxorubicin, bleomycin, vinblastine and dacarbazine (ABVD) in older patients with classical Hodgkin lymphoma (cHL) who were treated within HD10 and HD11 trials. It references a study by B. Böll et al, published in a 2013 issue of...

  • Cancer Chemotherapy Update. Solimando Jr., Dominic A.; Waddell, Aubrey // Hospital Pharmacy;Oct2009, Vol. 44 Issue 10, p858 

    The complexity of cancer chemotherapy requires pharmacists be familiar with the complicated regimens and highly toxic agents used. This column reviews various issues related to preparing, dispensing, and administering antineoplastic therapy and to the agents, commercially available and...

  • Standard and Increased-Dose BEACOPP Chemotherapy Compared with COPP-ABVD for Advanced Hodgkin's Disease. Diehl, Volker; Franklin, Jeremy; Pfreundschuh, Michael; Lathan, Bernd; Paulus, Ursula; Hasenclever, Dirk; Tesch, Hans; Herrmann, Richard; Dorken, Bernd; Müller-Hermelink, Hans-Konrad; Dühmke, Eckhardt; Loeffler, Markus // New England Journal of Medicine;6/12/2003, Vol. 348 Issue 24, p2386 

    Background: Faced with unsatisfactory results of treatment for advanced Hodgkin's disease, we investigated three combinations of chemotherapy. Methods: From 1993 to 1998, 1201 eligible patients 15 to 65 years of age who had newly diagnosed Hodgkin's disease in unfavorable stage IIB or IIIA or...

  • Involved-Field Radiotherapy for Advanced Hodgkin's Lymphoma. Aleman, Berthe M.P.; Raemaekers, John M.M.; Tirelli, Umberto; Bortolus, Roberto; van 't Veer, Mars B.; Lybeert, Marnix L.M.; Keuning, Jo J.; Carde, Patrice; Girinsky, Théodore; van der Maazen, Richard W.M.; Tomšič, Radka; Vovk, Marjeta; van Hoof, Achilles; Demeestere, Geertrui; Lugtenburg, Pieternella J.; Thomas, José; Schroyens, Wilfried; De Boeck, Koenraad; Baars, Johanna W.; Kluin-Nelemans, Johanna C. // New England Journal of Medicine;6/12/2003, Vol. 348 Issue 24, p2396 

    Background: The use of involved-field radiotherapy after chemotherapy for advanced Hodgkin's lymphoma is controversial. Methods: We randomly assigned patients with previously untreated stage III or IV Hodgkin's lymphoma who were in complete remission after hybrid chemotherapy with...

  • Antineoplastics.  // Reactions Weekly;10/21/2006, Issue 1124, p6 

    The article presents the case of a 31-year-old man who developed telangiectasia after receiving antineoplastic therapy with doxorubicin, bleomycin, vinblastine and dacarbazine for Hodgkin's disease. It references a study by M. Rodríguez-Martín et al, published in the September 2006 issue...

  • Factors affecting intrapatient liver and mediastinal blood pool F-FDG standardized uptake value changes during ABVD chemotherapy in Hodgkin's lymphoma. Chiaravalloti, Agostino; Danieli, Roberta; Abbatiello, Paolo; Pietro, Barbara; Travascio, Laura; Cantonetti, Maria; Guazzaroni, Manlio; Orlacchio, Antonio; Simonetti, Giovanni; Schillaci, Orazio // European Journal of Nuclear Medicine & Molecular Imaging;Jun2014, Vol. 41 Issue 6, p1123 

    Purpose: The aim of our study was to assess the intrapatient variability of 2-deoxy-2-(F)-fluoro- D-glucose (F-FDG) uptake in the liver and in the mediastinum among patients with Hodgkin's lymphoma (HL) treated with doxorubicin (Adriamycin), bleomycin, vinblastine and dacarbazine (ABVD)...

  • Non-growing follicle density is increased following adriamycin, bleomycin, vinblastine and dacarbazine (ABVD) chemotherapy in the adult human ovary. McLaughlin, M.; Kelsey, T. W.; Wallace, W. H. B.; Anderson, R. A.; Telfer, E. E. // Human Reproduction;Jan2017, Vol. 32 Issue 1, p165 

    Study Question: Do the chemotherapeutic regimens of ABVD (adriamycin, bleomycin, vinblastine and dacarbazine) or OEPA-COPDAC (combined vincristine, etoposide, prednisone, doxorubicin (OEPA) and cyclophosphamide, vincristine, prednisone, dacarbazine (COPDAC)) used to treat Hodgkin...

  • Four-cycle ABVD more toxic for older patients with Hodgkin's lymphoma.  // Hem/Onc Today;5/25/2013, Vol. 14 Issue 10, p31 

    The article discusses the findings of a study which revealed a significant dose reduction, delay in treatment, toxicity and treatment-associated mortality among patients aged at least 60 years with early-stage Hodgkins lymphoma who took four cycles of treatment with doxorubicin, bleomycin,...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics